Protocol Ledger

NCT06009861 · Phase II · ACTIVE NOT RECRUITING

Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)

Interventional Phase II clinical trial protocol NCT06009861 sponsored by Peking University Hospital of Stomatology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-27 Enrollment: 110 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06009861
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)110 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06009861
Protocol FieldVerified Registry Value
NCT IdentifierNCT06009861
Consolidated Lead SponsorPeking University Hospital of Stomatology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment110 participants (ESTIMATED)
Registered Start Date2023-06-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI